Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unazin Cold is a multi-ingredient combination medication marketed by Fawn Incor for the symptomatic relief of the common cold, influenza, and associated upper respiratory tract symptoms. It is available in two primary formulations: an oral suspension and an oral tablet. The suspension formulation (Unazin Cold Suspension) is composed of paracetamol (acetaminophen) for pain and fever relief, phenylephrine hydrochloride as a nasal decongestant, chlorpheniramine maleate as an antihistamine to reduce allergic symptoms, sodium citrate as a mucolytic/expectorant, and menthol for its soothing local anesthetic properties. The tablet formulation contains paracetamol, phenylephrine, diphenhydramine, and caffeine. Together, these components work synergistically to alleviate nasal congestion, runny nose, sneezing, sore throat, headache, and fever.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Unazin Cold.